
SELLAS Life Sciences prices $150M public offering to fund cancer therapy development
SELLAS Life Sciences Group, a biopharmaceutical company focused on cancer therapies, announced the pricing of an underwritten public offering of 11.5 million shares at $13 each, raising approximately $150 million before expenses. The offering include...


